This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Mar 2015

Actavis Launches Generic Version of Temovate

Actavis ahs announced that it has launched a generic version of Fougera's Temovate (clobetasol cream 0.05%) in the US. The launch strengthens Actavis' growing portfolio of valuable topical products and demonstrates the deep expertise of the company's global R&D and supply chain capabilities.

 

Temovate is a high-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

 

For the 12 months ended 15 January 2015, Temovate had total US brand and generic sales of approximately $185 million, according to IMS Health data.

Related News